Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Remington

Showing results (11-20 of 410) with videos related to

Pageof 41
Sort By:
Frontiers in Psychiatry|June 5, 2012
Interpreting a multivariate analysis of functional neuroimaging dataGagan Fervaha, Gary Remington
The American Journal of Psychiatry|January 9, 2014
Adequate dosing for second-generation antipsychotics in establishing treatment resistance in schizophreniaJimmy Lee, Gary Remington
Journal of Psychopharmacology (Oxford, England)|May 26, 2020
Immediate versus wait-and-gradual discontinuation in antipsychotic switching: A meta-analysisHiroyoshi Takeuchi, Gary Remington
Psychopharmacology|February 18, 2005
Predictors and markers of clozapine responseCarmen Chung, Gary Remington
Psychiatric Services (Washington, D.C.)|August 10, 2005
Overstating the case about recovery?Gary Remington, Chekkera Shammi
Journal of Clinical Psychopharmacology|May 1, 2012
Is psychiatry ignoring suicide? The case for clozapineMark Sinyor, Gary Remington
CNS Spectrums|July 27, 2004
The use of pharmacotherapy in the prodrome of schizophreniaGary Remington, Chekkera Shammi
The American Journal of Psychiatry|December 7, 2005
Remission: what's in a name?Gary Remington, Shitij Kapur
Evidence-Based Mental Health|October 14, 2015
Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reductionHiroyoshi Takeuchi, Gary Remington
Evidence-Based Mental Health|January 30, 2009
Review: insufficient evidence to guide use of drugs for clozapine induced hypersalivationSanjeev Sockalingam, Gary Remington
Pageof 41

Showing results (11-20 of 410) with videos related to

Sort By:
Pageof 41
Frontiers in Psychiatry|June 5, 2012
Interpreting a multivariate analysis of functional neuroimaging dataGagan Fervaha, Gary Remington
The American Journal of Psychiatry|January 9, 2014
Adequate dosing for second-generation antipsychotics in establishing treatment resistance in schizophreniaJimmy Lee, Gary Remington
Journal of Psychopharmacology (Oxford, England)|May 26, 2020
Immediate versus wait-and-gradual discontinuation in antipsychotic switching: A meta-analysisHiroyoshi Takeuchi, Gary Remington
Psychopharmacology|February 18, 2005
Predictors and markers of clozapine responseCarmen Chung, Gary Remington
Psychiatric Services (Washington, D.C.)|August 10, 2005
Overstating the case about recovery?Gary Remington, Chekkera Shammi
Journal of Clinical Psychopharmacology|May 1, 2012
Is psychiatry ignoring suicide? The case for clozapineMark Sinyor, Gary Remington
CNS Spectrums|July 27, 2004
The use of pharmacotherapy in the prodrome of schizophreniaGary Remington, Chekkera Shammi
The American Journal of Psychiatry|December 7, 2005
Remission: what's in a name?Gary Remington, Shitij Kapur
Evidence-Based Mental Health|October 14, 2015
Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reductionHiroyoshi Takeuchi, Gary Remington
Evidence-Based Mental Health|January 30, 2009
Review: insufficient evidence to guide use of drugs for clozapine induced hypersalivationSanjeev Sockalingam, Gary Remington
Pageof 41